Publications
Find coverage of the latest original articles on Lupus, focusing on those with data on therapeutic interventions and those that have clinical impact.
September 2024
CD19-CAR T-cell therapy induces deep tissue depletion of B cells
Ann Rheum Dis 2024;0:1–8 DOI 10.1136/ard-2024-226142
Tur et al. demonstrated that CD19-targeting CAR T-cell therapy results in the depletion of B cells within deep tissues. The study highlights significant reductions in pathogenic B-cell populations, particularly in autoimmune diseases, after CD19-CAR T-cell administration.
Keywords:
April 2024
CD19 CAR T-Cell therapy in autoimmune disease - A case series with follow-up
N Engl J Med 2024;390(8):687–700 DOI 10.1056/NEJMoa2308917
In this case series by Müller, et al., eight patients who received a CD19 CAR T-cell infusion achieved Definition of Remission in SLE (DORIS) remission, Lupus Low Disease Activity State and a SLEDAI 2K score of 0 at 6 months post-infusion. Long-term follow-up through 24 months showed that SLE disease activity remained absent
in all eight patients.
Keywords:
November 2022
Anti-CD19 CAR T Cell Therapy for Refractory Systemic Lupus Erythematosus
Nat Med. 2022;28(10):2124–2132 doi: 10.1038/s41591-022-02017-5
Data suggest that CD19 chimeric antigen receptor (CAR) T cell transfer is feasible, tolerable and highly effective in patients with SLE.